Internal Medicine, Endocrinology, Diabetes, & Metabolism · Philadelphia, PA
NPI
1003129685
Since 2010
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
9880 Bustleton Ave, Suite 220
Philadelphia, PA, 19115
Phone (215) 827-1500
Groups this clinician bills Medicare through
Medicare paid, 2024
$89K
1,289 services
Medicare patients, 2024
443
Average age 74
Drug cost, 2024
$4.3M
12,651 prescriptions
Company payments, 2025
$4,121
From 34 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Janna Prater was code 99214 (office e&m - established), 537 times for 326 patients. In total Janna Prater billed 1,289 services in 19 codes, and Medicare paid $89K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-07-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 537 | 326 | $93.57 | $50K |
| 99232 Hospital E&M - Subsequent | Facility | 250 | 71 | $67.27 | $17K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 171 | 137 | $13.51 | $2,310 |
| 96372 Injection Administration | Office | 100 | 55 | $10.69 | $1,069 |
| 95251 Test - Miscellaneous | Office | 84 | 50 | $28.51 | $2,395 |
| 99222 Hospital E&M - Initial | Facility | 42 | 40 | $111.68 | $4,691 |
| 99204 Office E&M - New | Office | 32 | 32 | $115.99 | $3,712 |
| 99213 Office E&M - Established | Office | 19 | 19 | $70.50 | $1,340 |
| 99215 Office E&M - Established | Office | 16 | 12 | $156.52 | $2,504 |
By year: 2022 $78K for 982 services; 2023 $88K for 1,145 services; 2024 $89K for 1,289 services.
Medicare prescription drug claims, 2024
In 2024, the drug Janna Prater prescribed most often to Medicare patients was Metformin Hcl, with 886 prescriptions and refills. In total Janna Prater wrote 12,651 Medicare prescriptions that cost $4.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Metformin Hcl Generic | 886 | 1,290 | 150 | $4,955 |
| Trulicity Dulaglutide | 835 | 894 | 118 | $843K |
| Levothyroxine Sodium Generic | 687 | 1,027 | 108 | $5,258 |
| Ozempic Semaglutide | 568 | 647 | 89 | $605K |
| Atorvastatin Calcium Generic | 514 | 788 | 89 | $3,452 |
| Farxiga Dapagliflozin Propanediol | 424 | 467 | 63 | $263K |
| Glipizide Generic | 378 | 538 | 65 | $2,902 |
| Jardiance Empagliflozin | 336 | 436 | 66 | $253K |
| Rosuvastatin Calcium Generic | 326 | 458 | 50 | $4,193 |
| Alendronate Sodium Generic | 307 | 370 | 58 | $1,692 |
| Glimepiride Generic | 289 | 394 | 47 | $2,156 |
| Synthroid Levothyroxine Sodium | 273 | 352 | 33 | $14K |
| Metformin Hcl Er Metformin Hcl | 253 | 367 | 41 | $4,188 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 234 | 398 | 66 | $17K |
| Pioglitazone Hcl Generic | 233 | 333 | 42 | $2,427 |
Brand drugs: 5,439 claims; generic drugs: 6,129 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Janna Prater $4,121 ($4,121 in general payments such as food, travel and fees) from 34 companies. The largest payer was Medtronic, Inc. with $986.
| Company | Payments | Amount |
|---|---|---|
| Medtronic, Inc. MDT | 19 | $986 |
| Novo Nordisk Inc NVO | 16 | $519 |
| Amgen Inc. AMGN | 14 | $250 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $244 |
| Xeris Pharmaceuticals, Inc. | 9 | $188 |
| Almatica Pharma LLC | 9 | $166 |
| Lilly USA, LLC LLY | 8 | $163 |
| Astellas Pharma US Inc 4503.T | 5 | $162 |
| Recordati_rare_diseases_inc. | 7 | $131 |
| Radius Health, Inc. | 4 | $126 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.